Synairgen plc (LON:SNG)‘s stock had its “corporate” rating reiterated by stock analysts at FinnCap in a research report issued on Wednesday. They presently have a GBX 137 ($1.70) price objective on the stock. FinnCap’s target price indicates a potential upside of 302.94% from the company’s previous close.

Separately, N+1 Singer lowered their target price on Synairgen plc from GBX 47 ($0.58) to GBX 46 ($0.57) and set a “buy” rating for the company in a report on Thursday, September 22nd.

Shares of Synairgen plc (LON:SNG) opened at 34.00 on Wednesday. Synairgen plc has a 1-year low of GBX 19.00 and a 1-year high of GBX 38.00. The company’s market cap is GBX 31.06 million. The company has a 50-day moving average price of GBX 33.73 and a 200-day moving average price of GBX 31.25.

Synairgen plc Company Profile

Synairgen plc is the United Kingdom-based holding company for Synairgen Research Limited, a respiratory drug discovery and development company. The Company is engaged in the licensing of inhaled interferon beta (IFN-b) program to AstraZeneca. Synairgen has a BioBank consisting of blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma or chronic obstructive pulmonary disease (COPD) (and relevant controls).

Receive News & Stock Ratings for Synairgen plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen plc and related stocks with our FREE daily email newsletter.